Table 2 Comparison of baseline clinical characteristics between the two groups of ALS patients.
From: Analysis of factors influencing sleep disorders in patients with amyotrophic lateral sclerosis
Variables | Total (n = 266) | ALS patients without sleep disorder (n = 90) | ALS patients with sleep disorder (n = 176) | Statistic | P |
|---|---|---|---|---|---|
FSS, mean ± SD | 33.36 ± 14.12 | 27.80 ± 13.72 | 36.21 ± 13.49 | t = − 4.78 | < .001 |
VAS, mean ± SD | 1.95 ± 1.54 | 1.66 ± 1.30 | 2.10 ± 1.63 | t = − 2.43 | 0.016 |
HARS, mean ± SD | 11.96 ± 7.86 | 7.51 ± 4.83 | 14.24 ± 8.15 | t = − 8.43 | < .001 |
HDRS, mean ± SD | 11.83 ± 7.27 | 8.91 ± 4.67 | 13.33 ± 7.89 | t = − 5.72 | < .001 |
ESS, mean ± SD | 3.22 ± 1.73 | 3.07 ± 1.73 | 3.30 ± 1.73 | t = − 1.05 | 0.297 |
ALSFRS-RB, mean ± SD | 10.06 ± 2.39 | 10.46 ± 2.25 | 9.85 ± 2.45 | t = 1.96 | 0.052 |
ALSFRS-RL, mean ± SD | 14.74 ± 5.88 | 16.02 ± 5.34 | 14.09 ± 6.04 | t = 2.57 | 0.011 |
ALSFRS-RR, mean ± SD | 10.86 ± 2.11 | 11.43 ± 1.51 | 10.57 ± 2.31 | t = 3.64 | < .001 |
ALSFRS-R, mean ± SD | 35.66 ± 8.50 | 37.91 ± 7.26 | 34.51 ± 8.87 | t = 3.35 | < .001 |
Disease progression rate, Mean ± SD | 1.71 ± 1.83 | 1.34 ± 1.27 | 1.90 ± 2.03 | t = − 2.40 | 0.017 |
Disease duration, mean ± SD | 17.44 ± 8.34 | 17.58 ± 7.92 | 17.37 ± 8.57 | t = 0.20 | 0.842 |
FVC, M (Q₁, Q₃) | 76.76 (63.80, 90.50) | 74.81 (62.31, 89.70) | 79.08 (69.56, 92.31) | Z = − 1.64 | 0.100 |
Age at onset, M (Q₁, Q₃) | 52.36 (44.99, 59.01) | 48.57 (42.48, 56.27) | 53.54 (47.06, 59.42) | Z = − 2.91 | 0.004 |
Site of onset, n(%) | χ2 = 0.00 | 0.963 | |||
Bulbar | 41 (15.41) | 14 (15.56) | 27 (15.34) | ||
Limb | 225 (84.59) | 76 (84.44) | 149 (84.66) | ||
EI escorial classification n(%) | – | 0.102 | |||
1 | 4 (1.50) | 2 (2.22) | 2 (1.14) | ||
2 | 31 (11.65) | 15 (16.67) | 16 (9.09) | ||
3 | 231 (86.84) | 73 (81.11) | 158 (89.77) |